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y@yahooAbstract Objectives: The objectives of this study were to estimate the levels of eotaxin, RANTES
and tumor necrosing factor-1 in allergic rhinitis and their relation to disease severity.
Study design: Prospective study.
Setting: Mansoura University Hospital.
Patients and methods: Twenty nine patients suffering from allergic rhinitis were included in this
study (19 patients with allergic rhinitis and 10 patients control group). The patients underwent esti-
mation of eotaxin, RANTES, TNF-1 in the nasal wash using Elisa technique. The patients were
divided according to the disease severity into mild allergic rhinitis, severe allergic rhinitis and con-
trol groups.
Results: The mean values of eotaxin, RANTES, TNF-1 in severe allergic rhinitis
(33.6 ± 11.07 pg/ml, 72.17 ± 87.61 pg/ml, 25.47 ± 4.04 pg/ml) were statistically higher than in
mild allergic rhinitis (9.80 ± 6.79 pg/ml, 10.50 ± 6.90 pg/ml, 12.99 ± 3.27 pg/ml) and the mean
values of all these parameters were higher in both groups compared to control group
(0.6 ± 0.69 pg/ml, 0.65 ± 0.74 pg/ml, 0.63 ± 0.54 pg/ml).Ear, Nose, Throat and Allied
evier B.V. All rights reserved.
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34 A.E. Sharkawy et al.Conclusion: This study suggests the role of local chemokines in the pathogenesis of allergic rhinitis
as well as their possible relation to the severity of the disease which may direct the attention to ther-
apeutic trials against these locally produced chemokines.
ª 2011 Egyptian Society of Ear, Nose, Throat and Allied Sciences.
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There is accumulating evidence that chemokines are involved
in both the migration and the activation of eosinophil and
other leukocytes during asthma responses. These chemokines
include RANTES, macrophage-inﬂammatory protein-11
(MIP-11), monocyte-chemotactic protein-3 (MCP-3), eotax-
in, and MCP-5.1 Eotaxin is the major eosinophil chemoat-
tractant that binds with high afﬁnity to chemokin receptor
3 (CCR3) which is expressed on cells such as eosinophils,
basophils, and Th-2 lymphocytes.2 It is secreted by multiple
cell types including epithelium, ﬁbroblasts, smooth muscle
cells, and eosinophils.3 Eotaxin family production by eosino-
phils results in the recruitment of eosinophils into the tissue
by a self-amplifying process in eosinophilic chronic rhinosi-
nusitis patients.4 All members of the Eotaxin family (Eotax-
in-1, -2 and -3) are involved in the pathogenesis of nasal
polyposis. The results are more likely indicative of a complex
cooperation between all members of the geotaxis family than
of a speciﬁc role in the development of eosinophilia and nasal
polyposis.5
RANTES is a broad-acting chemokine that has an estab-
lished role in the recruitment of CD4+ T cells, monocytes,
and eosinophils into inﬂammatory sites, and is upregulated
in patients with asthma. It is produced by numerous lung cell
types including CD8+ T cells and bronchial epithelial cells.6
Fujikura et al.7 investigated the expression of RANTES, and
eotaxin in the nasal mucosa of patients with allergic rhinitis
to clarify the effect of histamine and antihistamine on the reg-
ulation of the expression of these Cysteine–Cysteine (CC) che-
mokines. They concluded that histamine may induce CC
chemokine production in the nasal mucosa of patients with
allergic rhinitis. They suggested that the regulation of hista-
mine-CC chemokine interaction could lead to new therapeutic
approaches for the treatment of nasal allergy. Nasal allergen
challenge induces the enhanced secretion of IL-17 and RAN-
TES in the lower airways of nonasthmatic patients with aller-
gic rhinitis.8
Although TNF-1 can cause the characteristic physiologi-
cal phenotype of asthma, namely airway hyper responsiveness
and eosinophilia, the fact that it is not a potent chemoattrac-
tant for eosinophils suggests that its effects on eosinophil
recruitment are indirect.9 Lilly et al.10 demonstrates that
TNF-1 and IL-1b rapidly and transiently induce the accu-
mulation of eotaxin mRNA in bronchial epithelial cell lines
and that this increase is associated with the intracellular
accumulation of eotaxin protein and its secretion into the cell
supernatant. TNF-1 produces a nasal inﬂammatory re-
sponse in humans that is characterized by late phase (i.e.,
24 h post challenge) neutrophil activity and plasma
exudation.11
The aim of this study was to evaluate the levels of eotaxin,
RANTES and tumor necrosing factor-1 in allergic rhinitis
and their possible relation to disease severity.2. Patients and methods
Ethical approval for this work was obtained by the Ethical
Committee Board of Faculty of Medicine, Mansoura Univer-
sity. This work was done in ORL department and Microbiol-
ogy and immunology departments in the period between
August 2007 and May 2008.
The study included 29 patients (19 patients with allergic rhi-
nitis and 10 control). The patients were selected from the out
patients clinic of the ORL department Mansoura university.
The diagnosis of allergic rhinitis was conﬁrmed by clinical his-
tory, clinical examination, and positive skin test for certain
allergen and elevated total serum IgE. The patients were clas-
siﬁed into three groups: group I (n= 10) patients with severe
allergic symptoms, group II (n= 9) patients with mild allergic
symptoms based on visual analogue scale (VAS).12 The previ-
ous groups were compared with nonsmoking subjects with no
positive skin-prick response to common aeroallergens or his-
tory of respiratory disease acted as a control group III
(n= 10).
2.1. Nasal wash samples
The nasal cavity was washed with 10 ml of physiological saline
warmed at 37 C by reciprocating the piston of the syringe 10
times on each side. Lavage ﬂuid was centrifuged for 20 min at
400·g. The supernatant was stored frozen at 30 C until
assayed.8
2.2. Measurement of eotaxin
Eotaxin was measured in nasal wash using ELISA technique.
The BioSource human Eotaxin (hEotaxin) ELISA was used
(BioSource, Nivelles, Belgium). Fifty microliters of the stan-
dard diluent buffer were added to the wells reserved for sam-
ples and zero well. Fifty microliters of standards, samples or
controls were added to the appropriate microtiter wells. One
hundred microliters of biotinylated anti-eotaxin solution were
pipette into each well. After incubation for 2 h, wells were aspi-
rated and washed. One hundred microliters Streptavidin-HRP
working solution were added to each well and incubated for
30 min and thereafter, wells were thoroughly aspirated and
washed. One hundred microliters of stabilized chromogen were
added to each well. After incubation for 30 min, 100 ll of stop
solution were added to each well. Absorbance of each well was
read at 450 nm.
2.3. Measurement of RANTES
RANTES was measured in nasal wash and polyp samples
using ELISA technique. The BioSource human RANTES
(hRANTES) ELISA was used (BioSource, Nivelles, Belgium).
Fifty microliters of the standard diluent buffer were added to
zero wells. Fifty microliters of standards, samples or controls
Table 1 Eotaxin, Rantes and TNF-1 and total serum IgE in different groups.
Eotaxin (pg/ml) RANTES (pg/ml) TNF-1 (pg/ml) Total IgE (IU/ml)
M SD M SD M SD M SD
Group I 33.6 11.07 72.17 87.61 25.47 4.04 626 281.78
Group II 9.80 6.79 10.50 6.90 12.99 3.27 593.9 286.23
Group III (control group) 0.6 0.69 0.65 0.74 0.63 0.54 31.5 11.03
P* <0.001 0.04 <0.001 0.803
P** <0.001 0.019 <0.001 <0.001
P*** <0.001 <0.001 <0.001 <0.001
* P (severe allergic rhinitis vs. mild allergic rhinitis).
** P (severe allergic rhinitis vs. control).
*** P (mild allergic rhinitis vs. control).




Pearson correlation 1.000 0.287 0.118
Sig. (2-tailed) – 0.421 0.745
RANTES (pg/ml)
Pearson correlation 0.287 1.000 0.525
Sig. (2-tailed) 0.421 – 0.119
TNF-1 (pg/ml)
Pearson correlation 0.118 0.525 1.000
Sig. (2-tailed) 0.745 0.119 –
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biotinylated anti-RANTES solution were pipette into each
well and incubated for 1 h. Wells were aspirated and washed.
One hundred microliters Streptavidin-HRP working solution
was added to each well. After incubation for 30 min, wells were
aspirated and washed and 100 ll of stabilized chromogen were
added to each well. After incubation for 30 min, 100 ll of stop
solution were added to each well. Absorbance of each well was
read at 450 nm.
2.4. Measurement of tumor necrosis factor-1
EASIA TM ELISA Kit (Biosource, Nivelles, Belgium) was
used. Fifty microliters incubation buffers were added to all
wells, 200 ll standards, controls, and samples were added
and incubated for 2 h. After washing with buffer, 100 ll of
standard zero were added to each well, 50 ll HRP-conjugate
were added and incubated for 2 h. After washing with buffer,
200 ll TMB chromogenic solutions were added to each well
and incubated for 30 min. Fifty microliters of stop solution
were added to each well and the absorbance was measured
at 450 nm.
2.5. Measurement of serum IgE by ELISA
Serum IgE was measured by ELISA kit (Elitech diagnostics –
France).
3. Results
This study is a prospective study that included 29 patients (19
patients with allergic rhinitis and 10 patients as control). The
patients were classiﬁed into three groups. Group I (10 patients)
with severe allergic rhinitis, group II (9 patients) with mild
allergic rhinitis and group III control group (10 patients). They
were 13 males and 17 females with mean age 29 ± 7 years.
From this study, the level of the eotaxin was higher in se-
vere allergic rhinitis (33.6 pg/ml) than in mild allergic rhinitis
(9.8 pg/ml) or control group (0.6 pg/ml) (Table 1).
Also, the level of the RANTES and TNF-1 were higher in
severe allergic rhinitis (72.17 and 25.47 pg/ml) than in mild
allergic rhinitis (10.5 and 12.99 pg/ml) or control group (0.65
and 0.63 pg/ml).
Total level of IgE was higher in severe allergic rhinitis
(626 IU/ml) than in mild allergic rhinitis (593.9 IU/ml) or
control group (31.5 IU/ml). The mean values of eotaxin,RANTES, TNF-1 and IgE in severe allergic rhinitis are statis-
tically higher than in mild allergic rhinitis and the mean values
of all these parameters were higher in both groups compared
to control group.
By studying the correlation between eotaxin, RANTES and
TNF-1 in severe allergic rhinitis, there was no positive corre-
lation between these cytokines in severe allergic rhinitis (Table
2). In mild allergic rhinitis, there was no positive correlation
between eotaxin, and RANTES, while positive correlation
was found between TNF-1 and both RANTES and eotaxin
(Table 3).
4. Discussion
Collins et al., 1996, reported that eotaxin had an important lo-
cal role in eosinophil recruitment from blood microvessels,
whereas IL-5 facilitates this process by acting remotely as a
hormone to stimulate the release of a rapidly mobilizable pool
of bone marrow eosinophils into the circulation.9 Hanazawa et
al., 2000, observed that intranasal administration of eotaxin
actually increases nasal eosinophils and nitric oxide in patients
with allergic rhinitis.10
In our study, the levels of eotaxin, RANTES, and TNF-1
in nasal wash were increased in mild and severe allergic rhinitis
compared to normal control, and these cytokines were in-
creased in severe cases compared to mild cases. The increased
eotaxin, RANTES, TNF-1 in severe cases suggests another
relation of these cytokines to disease severity and suggests a
possible role for these cytokines in pathogenesis of allergic rhi-
nitis at the nasal mucosa.




Pearson correlation 1.000 0.505 0.773**
Sig. (2-tailed) – 0.137 0.009
RANTES (pg/ml)
Pearson correlation 0.505 1.000 0.885**
Sig. (2-tailed) 0.137 – 0.001
TNF-1 (pg/ml)
Pearson correlation 0.773** 0.885** 1.000
Sig. (2-tailed) 0.009 0.001 –
** Correlation is signiﬁcant at the 0.01 level (2-tailed).
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moattractants in nasal lavage ﬂuids obtained after antigen
challenge, compared with eosinophil counts and eosinophil
protein X (EPX) levels.8 In subjects with allergic rhinitis, aller-
gen challenge led to parallel increases in eosinophil counts, lev-
els of EPX, and eotaxin concentrations in nasal lavage ﬂuid.
The levels of eotaxin in lavage samples showed strong correla-
tion with lavage levels of eosinophil counts and EPX. These re-
sults indicate that eotaxin has an important role in eosinophil
dependent inﬂammation in nasal mucosa and suggest that
blocking eotaxin or CCR-3 might be useful for new therapeu-
tic tools of allergic rhinitis.
Sim et al.13 demonstrated that RANTES were released in
nasal ﬂuid after allergen challenge in allergic subjects and the
levels correlated with corresponding total symptom scores
during late-phase response. However, Terada et al. detected
RANTES in only 19 of 70 samples of nasal lavage ﬂuids ob-
tained before and after allergen challenge in allergic subjects.8
They indicated that other samples contained RANTES below
the sensitivity of the assay they used. Moreover, no signiﬁcant
correlation was observed between RANTES and eosinophil
counts or EPX. They concluded that the relative role of RAN-
TES in eosinophilic inﬂammation in nasal mucosa remains to
be established.
Correlations were not found between eotaxin and RAN-
TES in severe and mild allergic rhinitis, however, the signiﬁ-
cant elevations in all these cytokines in the previous
conditions indicate that they have complementary functions.
Ponath et al.9 indicated that the higher levels of eotaxin
immunoreactivity in nasal epithelial cells at sites of active
allergic inﬂammation where cytokines including TNF-1 and
IL-1b are known to be available as opposed to adjacent non-
inﬂamed, non-cytokine-expressing epithelium imply the
existence of a mechanism modulating eotaxin production in
allergic airway disease that may involve these cytokines.
Bartels et al.14 found elevated expression of eotaxin- and
RANTES-mRNA but no MCP-3 mRNA in non-atopic and
atopic nasal polyps when compared to normal nasal mucosa.
In nasal polyposis, allergic rhinitis and both allergic and non-
allergic sinusitis, upregulation of eotaxin mRNA and protein
has been detected.6
Nonaka et al.15 concluded that a co-stimulus like lipopoly-
saccharide is necessary for IL-4 to make a strong induction of
eotaxin in eosinophilic inﬂammation.Recent studies indicate that (YM-355179) is a novel, selec-
tive, and orally available CCR3 antagonist (chemokine recep-
tor antagonist) with therapeutic potential for treating
eosinophil-related allergic inﬂammatory diseases.16
Zhang et al.17 stated that the T helper cell (T(H)) immune
system is not well regulated in allergic rhinitis. Most of the
upregulated genes are of chemokines and their receptors that
play important roles in T(H)2 response, and some are involved
in the induction of allergic reaction, accumulation of inﬂam-
matory cells, and degranulation of sensitized cells. These
ﬁndings can point to new strategies for allergic rhinitis immu-
notherapy. Studies will lead to the identiﬁcation of novel
CCR3 chemokine receptor antagonists, which can be thera-
peutically used in allergic asthma, allergic rhinitis, and atopic
dermatitis.18
In conclusion, we suggest possible roles for eotaxin,
RANTES and TNF-1 at the local level in the pathogenesis
of allergic rhinitis and their possible relation to disease severity
which direct the attention to therapeutic trials for these locally
produced cytokines.
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